A Phase 1/2a Single Dose-Escalating Study to Evaluate the Safety, Tolerability and Pharmacokinetic Effects of ARO-HBV in Normal Adult Volunteers and Multiple Escalating Doses Evaluating Safety, Tolerability and Pharmacodynamic Effects in HBV Patients
Phase of Trial: Phase I/II
Latest Information Update: 13 Mar 2018
At a glance
- Drugs ARO-HBV (Primary)
- Indications Hepatitis B
- Focus Adverse reactions; First in man
- Sponsors Arrowhead Pharmaceuticals
- 08 Mar 2018 Status changed from not yet recruiting to recruiting.
- 07 Mar 2018 Planned initiation date changed from 5 Mar 2018 to 27 Mar 2018.
- 15 Feb 2018 According to an Arrowhead Pharmaceuticals media release, the company anticipates that dosing will begin around the end of March.